| __timestamp | Amicus Therapeutics, Inc. | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 2917513 |
| Thursday, January 1, 2015 | 47269000 | 7878291 |
| Friday, January 1, 2016 | 71151000 | 8366794 |
| Sunday, January 1, 2017 | 88671000 | 6610381 |
| Monday, January 1, 2018 | 127200000 | 6556000 |
| Tuesday, January 1, 2019 | 169861000 | 6930000 |
| Wednesday, January 1, 2020 | 156407000 | 8758000 |
| Friday, January 1, 2021 | 192710000 | 10806000 |
| Saturday, January 1, 2022 | 213041000 | 9844000 |
| Sunday, January 1, 2023 | 275270000 | 13481000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Over the past decade, Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting approaches. From 2014 to 2023, Amicus Therapeutics increased its SG&A expenses by over 1,200%, peaking at approximately $275 million in 2023. This aggressive spending reflects their commitment to expanding market reach and operational capabilities. In contrast, Soleno Therapeutics maintained a more conservative growth, with SG&A expenses rising by about 360% to $13.5 million in the same period. This cautious approach may indicate a focus on lean operations and targeted investments. These spending patterns highlight the diverse strategies within the biotech sector, where companies must balance growth ambitions with financial prudence.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: AbbVie Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Soleno Therapeutics, Inc. Trends and Insights
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.